This year in the United States, nearly 270,000 women will receive the devastating news that they have breast cancer. Many will choose breast-conserving surgery, commonly referred to as lumpectomy, wherein the surgeon seeks to remove the malignant tumor, while also preserving as much healthy breast tissue as possible.
The number of approved cancer therapies continues to rise, with 63 cancer drugs launched within the past five years.
Philip J. Stella, the principal investigator of the Michigan Cancer Research Consortium NCI Community Oncology Research Program site in Ann Arbor, won the 2019 Harry Hynes Award.
According to the National Cancer Institute (NCI), 1,735,350 people were newly diagnosed with cancer in 2018. Of those, 65% are expected to achieve remission from their cancer 1.
The founding partners of the Lung Ambition Alliance launched the group July 8 with the primary objective of doubling five-year survival rates for patients with lung cancer—up to 40%.
The recently formed Lung Ambition Alliance seeks to double the five-year survival rate for lung cancer—up to 40%, by 2025.
Amarinthia Curtis has a community doctor's perspective on the scientific questions the Tomosynthesis Mammographic Imaging Screening Trial seeks to address.
Nearly three years after its introduction, the CMS's Oncology Care Model (OCM) remains the most ambitious and far-reaching initiative to shift cancer care toward value-based models.
The Cancer Letter won four 2019 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists:
The FDA Oncology Center of Excellence announced a pilot program to help physicians get access to unapproved therapies for patients with cancer.
